Sorafenib 200mg

Sorafenib belongs to the pharmacological group of antitumor agents. The active substance in this drug is sorafenib. Sorafenib 200 mg is used in the treatment of metastatic renal cancer, as well as hepatic cell carcinoma. Even with metastatic disease, recovery is possible.

Mechanism of action of the drug

Sorafenib is able to block simultaneously the activity of several enzymes, which belong to the class of kinases and are on the surface, and also directly inside the tumor cells. Such enzymes are important in the process of reproduction of malignant cells, as well as with the formation of a network of vessels inside the tumor, which ensure its vital activity. The drug makes it possible to suppress the enzymatic activity, inhibiting the processes of cell proliferation, preventing the growth of the tumor.

Application of the drug

The standard daily dose of the drug is 800 mg, which must be divided into several intakes. The drug is taken in the morning and in the evening for 2 tablets, which contain 200 mg of sorafenib in each. Sorafenib is taken between meals together with food, but the dishes should not be too greasy. Tablets should be taken with a glass of water. Reception of the drug can last for a long time, and it can continue until a clinical outcome is achieved or until the patient has significant complications. But in this case, you can reduce the manifestation of negative symptoms, temporarily stop taking the drug or reduce the dose to 200-400 mg.

The most frequent adverse reactions with Sorafenib 200 mg were skin reactions in the limbs (palmar-plantar erythrodysesthesia) and rash. In most cases, they were the first and second degree of severity and were manifested, mainly, during the first 6 weeks of treatment with Sorafenib 200 mg. To treat skin toxic reactions, local drugs with symptomatic effect can be used. If necessary, temporarily stop treatment and / or change the dose of Sorafenib or, in severe or recurrent skin reactions, Sorafenib therapy is canceled.

Patients with disseminated renal cell carcinoma (RCC) constitute a special group of patients who until recently have been offered only cytokine therapy, which unfortunately is effective only in 15% of cases and has serious side effects. In recent years, the situation has changed, we have witnessed the emergence of principally new drugs, purposefully blocking certain links in the tumor pathogenesis of targeted drugs.

Among antitumor drugs, Sorafenib is particularly prominent. It is the first representative of a new generation of anti-angiogenic drugs, multikinase inhibitors, whose action is realized in several directions.

Sorafenib 200 mg specifically suppresses signaling pathways that activate tumor growth.
This drug slows the progression of advanced liver cancer and helps some patients with this form of cancer live longer.

The efficacy and safety of the drug was studied during three large-scale clinical trials. Based on the data that were obtained as a result of the ongoing studies, the use of Sorafenib 200 mg allowed to double the survival rates of patients, while the disease did not progress. In particular, a pronounced clinical response to the therapy was obtained in more than 70% of patients.